beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques
about
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesPerforin-low memory CD8+ cells are the predominant T cells in normal humans that synthesize the beta -chemokine macrophage inflammatory protein-1betaProtection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsApproaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.A rational basis for mucosal vaccination against HIV infection.Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.Human peripheral blood T cells, monocytes, and macrophages secrete macrophage inflammatory proteins 1alpha and 1beta following stimulation with heat-inactivated Brucella abortus.Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.The role of immunity in protection from mucosal SIV infection in macaques.Control of HIV-1 infection by soluble factors of the immune response.CC chemokines and protective immunity: insights gained from mother-to-child transmission of HIV.Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infectionsISCOM-based vaccines: the second decade.Immune pathogenesis of pediatric HIV-1 infection.Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmissionImmunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine productionQualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection.Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag cThe nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells.Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus.Antibodies raised to short synthetic peptides with sequences derived from HIV-1 SF2 gp120 can both neutralize and enhance HIV-1 SF13: a later variant isolated from the same host.
P2860
Q22241377-882899E1-B06B-470D-A66A-60B48AD8A853Q24555821-46663C0F-BDF5-4F45-B56F-ACB1214AD789Q33737723-7713C291-6974-42E4-B518-BBF3EBC91066Q33776155-157E53B8-7AAD-4B99-BFDC-C9CC67FF9884Q33776167-93A037D7-FC0C-45EA-A4AE-A652EF0B6499Q33787256-3E809B2F-B65B-4FD6-9BE8-5A38CAB11303Q33788861-B220B0C7-0F70-44B8-BB23-719F3746BDD5Q33803217-7E6FC6A1-ACE6-48ED-BD81-00541403D0B1Q33813526-403C6790-3345-4235-9515-435D81D1F695Q33843554-1D1695FD-3CB4-48C1-83C6-769FCD1FB753Q34007794-7225F505-FF64-403D-818E-42D5FCA7AF02Q34053295-51968094-FE19-4490-9810-4D6819A21393Q34117097-3D3E41A6-D08F-4CE1-A6AE-5965505BA4CFQ34227778-99412D26-865A-4DC4-9E46-92658CBB423EQ34775270-C90C4F7A-E9B4-4313-ABC0-0EC6F1B5BD3DQ35752416-F76ED556-1908-4D34-82C4-4939984DFD94Q35785527-D98F622A-122F-4942-BC12-C836034BF5E1Q35857480-F6E79FDE-2096-47D9-83B1-0EFE1AB6CB26Q36062124-64CC12B9-1885-4352-947C-A56C11873F31Q36415769-EEA4B53B-D4CE-4C7C-8EFB-1E3302D7CE17Q36628269-B9D9C705-7427-48F6-8DB0-6539816269F1Q36706780-9641710C-2F2E-4754-AE58-A2D38E99F937Q37009569-B566F332-6850-4DA2-8D3A-1DF26AD39A7BQ38658529-0774DE14-D3EA-4940-B5DF-74449037E1B1Q38749319-55CC6092-C84A-47E5-8BB3-9C27B1B9442FQ39028785-390F5D64-9D0E-4E43-AFCD-6F10C7185981Q45059085-916D1F12-E5BB-47C2-A945-461D40652368Q45745783-2608765C-C7D6-4FD8-9077-1470D1721C26Q52843657-76CE7157-6C40-4935-9E18-0C163B0C7E6F
P2860
beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
beta-chemokines and neutralizi ...... d in HIV-1 vaccinated macaques
@ast
beta-chemokines and neutralizi ...... d in HIV-1 vaccinated macaques
@en
beta-chemokines and neutralizi ...... in HIV-1 vaccinated macaques.
@nl
type
label
beta-chemokines and neutralizi ...... d in HIV-1 vaccinated macaques
@ast
beta-chemokines and neutralizi ...... d in HIV-1 vaccinated macaques
@en
beta-chemokines and neutralizi ...... in HIV-1 vaccinated macaques.
@nl
prefLabel
beta-chemokines and neutralizi ...... d in HIV-1 vaccinated macaques
@ast
beta-chemokines and neutralizi ...... d in HIV-1 vaccinated macaques
@en
beta-chemokines and neutralizi ...... in HIV-1 vaccinated macaques.
@nl
P2093
P2860
P356
P1476
beta-chemokines and neutralizi ...... d in HIV-1 vaccinated macaques
@en
P2093
C De Giuli Morghen
J L Heeney
L Akerblom
M van Gils
V J Teeuwsen
W M Bogers
P2860
P304
10803-10808
P356
10.1073/PNAS.95.18.10803
P407
P577
1998-09-01T00:00:00Z